Part 1: HIV Testing

 

1. CD4 Baseline Testing

CD4 cell count testing at baseline for all people living with HIV 

The 2017 WHO guidelines point out that CD4 cell count testing at baseline for all people living with HIV remains important, because relying on clinical staging alone risks missing substantial numbers of people living with HIV with severe immune suppression.

In a study from Kenya, Malawi, Uganda, and Zimbabwe, almost half the people with CD4 count <100 cells/µl were classified as having WHO clinical stage 1 or 2 disease.1 Hence, identifying people with advanced HIV disease who are eligible for elements of a package of care requires CD4 cell count testing.

All patients entering or re-entering care should receive a CD4 test at treatment baseline and as clinically indicated for patients who are unstable or with advanced HIV disease.2

FLOWC_HIV CD4 Button What is CD4 - Section 4

2. Identification of Advanced HIV Disease

Definition of advanced HIV disease 
People presenting with advanced HIV disease are at high risk of death. The 2017 WHO guidelines define advanced HIV disease as follows:

  1. For adults and adolescents, and children older than five years, advanced HIV disease is defined as CD4 cell count <200cells/µl or WHO stage 3 or a 4 event. 
  2. All children younger than five years old with HIV are considered as having advanced HIV disease. 
  3. A severely immunosuppressed adult is defined as having a CD4 cell count <50cells/µl.

 

People presenting with advanced HIV disease are at high risk of death, even after starting ART, with the risk increasing with decreasing CD4 cell count, especially with CD4 cell count <100 cells/µl.4 Relying on clinical staging alone risks missing substantial numbers of people living with HIV with severe immune suppression.1 Advanced HIV disease package of care People with advanced HIV disease are defined as those presenting to care with a CD4 count below 200 cells/µl or WHO disease stages 3 and 4. 

 The package of care for these people should include the following:

  1. Rapid initiation of ART (once the risk of immune reconstitution inflammatory syndrome [IRIS] is ruled out); 
  2. Systematic screening for Cryptococcus antigen; 
  3. Screening and treatment for tuberculosis (TB) or isoniazid preventive treatment (IPT) as indicated; 
  4. Screening for toxoplasmosis and Co-trimoxazole (CTX) prophylaxis; and
  5. Intensive follow-up. 3

3. Laboratory & Diagnostic Services

Effective laboratory and diagnostic services
Even in settings with full access to viral load testing, CD4 cell count testing capability will continue to be needed as part of HIV programs for baseline risk and other clinical assessments. Depending on the context, as the transition to viral load monitoring from CD4 count testing for initiation and monitoring progresses, programs may wish to consider centralizing the continued use of CD4 count testing.17 

Continue to the next section of Beckman Coulter Life Sciences’ “Twelve Steps to CD4 Testing.” 

References 

1,. World Health Organization (2017): Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, page 6.

2. World Health Organization (2017): What’s new in treatment monitoring: Viral load and VCD4 testing Information Note WHO/HIV/2017.22, page 1

3. World Health Organization (2017): Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, page v. 

4. World Health Organization (2017): Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, page 2.

5. World Health Organization (2016): Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection;  recommendations for a public health approach – 2nd ed., page 241.

17. World Health Organization (2016): Consolidated guidelines on the use of antiretroviral drugs or treating and preventing HIV infection; recommendations for a public health approach – 2nd ed., pages 295-297.

 

FREE Educational wall poster

outlining the new role of

CD4 in the WHO Guidelines

FLOWC-HIV CD4 Booklet front cover - Section 4

Contact Us


















Please keep me informed about Beckman Coulter webinars, products, goods, and services, including products, goods, or services from our related companies.



By submitting this form I confirm that I have reviewed and agree with the Privacy Policy and Terms of Use. I also understand my privacy choices as they pertain to my personal data as provided in the Privacy Policy under “Your Privacy Choices”.

Twelve Steps To CD4 Testing

WHO Guidelines CD4 Testing​

The 2016 and 2017 World Health Organization (WHO) guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the care of people living with HIV, and the use of antiretroviral (ARV) drugs for treating and preventing HIV infection.

12 Steps to CD4 Testing​ Part I: HIV Testing

The 2017 WHO guidelines point out that CD4 cell count testing at baseline for all people living with HIV remains important, because relying on clinical staging alone risks missing substantial numbers of people living with HIV with severe immune suppression.1 

12 Steps to CD4 Testing​ Part II: HIV Treatment

Recommendation for rapid initiation of ART People with no contraindication to rapid ART initiation should be fully informed of the benefits of ART and offered rapid ART initiation, including the option of  same-day initiation


12 Steps to CD4 Testing​ Part III: HIV & Opportunistic Infections

Co-trimoxazole prophylaxis is recommended for infants, children and adolescents with HIV, irrespective of clinical and immune conditions. Priority should be given to all children younger than 5 years old regardless of CD4 cell count or clinical stage.